艾愈胶囊治疗卵巢癌的疗效观察与药物经济学分析

Curative Efficay and Pharmacoeconomics of Aiyu Capsule in Treatment of Ovarian Cancer

目的:观察艾愈胶囊治疗卵巢癌的疗效和药物经济学情况。方法:选择2007年11月—2012年11月收治的卵巢癌患者120例,以随机数字表法分为治疗组60例、对照组60例。治疗组患者采用艾愈胶囊辅助治疗,对照组患者使用安慰剂辅助化疗。观察2组患者治疗后的临床疗效、安全性,并采用成本-效果分析模型进行药物经济学分析。结果:治疗组患者总有效率为90.0%(54/60),对照组为73.3%(44/60),2组差异有统计学意义(P<0.05);治疗后,治疗组仅9例患者出现不良事件,明显优于对照组的21例,2组差异有统计学意义(P<0.05);治疗组的成本-效果比为40.57,对照组为46.73,2组差异有统计学意义(P<0.05)。结论:艾愈胶囊辅助化疗治疗卵巢癌安全、有效、经济,是相对合理的治疗药物,值得推广应用。

OBJECTIVE：To evaluate the curative efficacy and pharmacoeconomics of Aiyu capsule in treatment of ovarian cancer.METHODS：120 patients with ovarian cancer treated in our hosptial between Nov.2007 and Nov. 2011 were randomly assigned to receive chemotherapy plus either Aiyu capsule as adjuvant therapy （ experimental group） or placebo （ control group） , of 60 cases each.The efficacy and safety in the two groups were followed and the pharmacoeconomics in the two groups was evaluated using cost-effectiveness model.RESULTS：The total effective rate of the experimental group was 90%, as compard with 73.3%of the control group, and the difference was statistically significant between the two groups （ P〈0.05 ） .Adverse events were noted in 9 cases of the experimental group versus 21 of the control group, and the difference between the two groups was statistically significant （ P〈0.05） .The cost-effectiveness ratio was 40.57 for the experimental group as against 46.73 for the control group, and the difference between the two groups was statistically significant （ P〈0.05 ） .CONCLUSIONS：Aiyu capsule added to chemotherapy was proved to be a safe, effective, economical and rational adjuvant therapy in treatment of ovarian cancer, which thus is worth of clinical recommendation.